Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail
Regeneron Pledges Update By Early 2022
New studies show Regeneron and Lilly’s leading COVID-19 antibody cocktails are ‘inactive’ against Omicron but there is better news for Vir, AstraZeneca and Adagio.
You may also be interested in...
The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.
The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2.
Public Company Edition: As their stock prices plummet, Adagio reshuffles its research plan and names a new CEO, while Yumanity restructures and seeks strategic alternatives. Also, Bristol sells $6bn worth of notes, Amgen issues $750m green bond, and Inhibrx and Amryt amend and refinance debt.